Clinical Trial Update: A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on REGN5678 (Nezastomig) alone or in combination with cemiplimab to treat metastatic castration-resistant prostate cancer and other tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Libtayo (cemiplimab)
• Nezastomig (REGN5678)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1, Phase 2 | Status: RECRUITING